We conclude that the synergy of high PF4 concentration, PF4/virus complexes, and PF4-antibodies or the synergistic COVID-HIT system majorly contributed to the development of unusual severe thrombotic thrombocytopenia in COVID-19 patients (Figure 4C). Here, PF4 is linked to COVID-19.